Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

Li Peng; Ding HuiGuo; Xu Hui; Zhang ShiBin; Zhang YueNing; Wang ZhenBiao; Wu YanJing; Yu HaiBin

doi:10.3969/j.issn.1001-5256.2017.07.019

Issue 7

Jul. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(7): 1301-1304

PDF( 1568 KB)

Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2017.07.019

Department of Gastroenterology and Hepatology, Beijing You An Hospital, Capital Medical University

Research funding:

Received Date: 2017-01-25
Published Date: 2017-07-20

Abstract

Abstract

Objective To investigate the influence of shortening liver cancer screening interval on the detection of early-stage hepatocellular carcinoma (HCC) in patients with hepatitis B cirrhosis and their prognosis, as well as proper screening schemes for such patients at a high risk of HCC.Methods A total of 310 patients with hepatitis B cirrhosis who were diagnosed and treated in Department of Gastroenterology and Hepatology, Beijing You An Hospital, from January 2007 to January 2008 were enrolled, and according to the screening interval, they were divided into 3-month screening group (group A) with 78 patients and 6-month screening group (group B) with 232 patients.The screening items included serum alpha-fetoprotein and ultrasound and the patients were followed up for 5 years.The patients with HCC screened out were followed up to the endpoint (death or December 31, 2016) .The detection of HCC and prognosis were compared between the two groups.The t-test was used for comparison of continuous data between groups, the chi-square test or Fisher's exact test was used for comparison of categorical data between groups, and the Kaplan-Meier method was used for survival analysis.Results At the end of the5-year follow-up, 73 patients were diagnosed with HCC, with 21 in group A and 52 in group B.Group A had a significantly higher proportion of patients with early-stage HCC (Barcelona Clinic Liver Cancer stage A) than group B [66.7% (14/21) vs 15.4% (8/52) , χ2=18.685, P<0.001].Group A also had a significantly higher proportion of patients who underwent radical surgery than group B (76.2% vs 36.5%, χ2=9.424, P=0.002) .The patients with HCC were followed up to the endpoint, and compared with group B, group A had a significantly longer cumulative survival time (66.4 ± 8.0 months vs 38.1 ± 4.5 months, t=4.295, P=0.038) and a significantly higher cumulative survival rate [71.4% (15/21) vs 46.2% (24/52) , χ2=3.840, P=0.043].Conclusion For patients with hepatitis B cirrhosis, a 3-month screening interval can increase the early detection rate of HCC, bring the opportunity of radical treatment for these patients, and prolong their survival time.
- hepatitis B virus,
- liver cirrhosis,
- carcinoma, hepatocellular,
- early diagnosis,
- prognosis

FullText(HTML)

References(20)

References

[1]QI JH, WANG J, KATAYAMA H, et al.Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma[J].Neoplasma, 2013, 60 (2) :135-142.

[2]VILANA R, FORNER A, GARCIA AN, et al.Hepatocellular carcinoma:diagnosis, staging, and treatment strategy[J].Radiologia, 2010, 52 (5) :385-398.

[3]KUDO M.The 2008 Okuda lecture:management of hepatocellular carcinoma:from surveillance to molecular targeted therapy[J].J Gastroenterol Hepatol, 2010, 25 (3) :439-452.

[4]OMATA M, LESMANA LA, TATEISHI R, et al.Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma[J].Hepatol Int, 2010, 4 (2) :439-474.

[5]BRUIX J, SHERMAN M, LLOVET JM, et al.Clinical management of hepatocellular carcinoma.Conclusion of the Barcelona-2000EASL Conference[J].J Hepatol, 2001, 35 (3) :421-430.

[6]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma-an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[7]LI P, CHEN YH, ZHANG SB, et al.Comparison of dierent hepatocarcinoma screening schemes for patients with hepatitis B associated cirrhosis:Detection rate and impact on prognosis[J].World Chin JDig, 2015, 20 (23) :3298-3303. (in Chinese) 李鹏, 陈玉涵, 张世斌, 等.乙型肝炎肝硬化患者不同肝癌筛查方案的比较及对预后影响[J].世界华人消化杂志, 2015, 20 (23) :3298-3303.

[8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.

[9]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部, 原发性肝癌诊疗规则 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[10]FORNER A, REIG ME, de l OPE CR, et al.Current strategy for staging and treatment:the BCLC update and future prospects[J].Semin Liver Dis, 2010, 30 (1) :61-74.

[11]LIN SM, LIN CJ, LIN CC, et al.Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less[J].Gut, 2005, 54 (8) :1151-1156.

[12]WANG JH, CHANGCHIEN CS, HU TH, et al.The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients[J].Eur JCancer, 2008, 44 (7) :1000-1006.

[13]TSENG PL, WANG JH, TUNG HD, et al.Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening[J].J Gastroenterol Hepatol, 2010, 25 (8) :1426-1434.

[14]KUO YH, LU SN, CHEN CL, et al.Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis[J].Eur J Cancer, 2010, 46 (4) :744-751.

[15]LLOVET JM, DUCREUX M, LENCIONI R.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].JHepatol, 2012, 56 (4) :908-943.

[16]STEFANIUK P, CIANCIARA J, WIERCINSKA-DRAPALO A.Present and future possibilities for early diagnosis of hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (4) :418-424.

[17]LIN H, ZHENG WD.The diagnosis and prognostic value of AFP, AFU, TSGF and IL-8 in liver transplantation patients with liver cancer[J].J Clin Exp Med, 2017, 16 (8) :776-780. (in Chinese) 林花, 郑卫东.AFP、AFU、TSGF及IL-8对肝癌患者诊断及肝移植术预后评估的价值研究[J].临床和实验医学杂志, 2017, 16 (8) :776-780.

[18]ZHU QX.Diagnostic value of joint detection of golgin 73, alphafetoprotein, alpha-fetoprotein variants for primary hepatocellular carcinoma[J].China Med Herald, 2016, 13 (5) :130-133. (in Chinese) 诸琴红.高尔基体蛋白73、甲胎蛋白、甲胎蛋白异质体3%联合检测对原发性肝癌的诊断价值[J].中国医药导报, 2016, 13 (5) :130-133.

[19]LI JL, SHAGN J, NING HB, et al.Role of serum abnormal prothrombin protein induced by vitamin K absence or antagonist-II in development and progression of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (1) :171-174. (in Chinese) 李俊利, 尚佳, 宁会彬, 等.PIVKA-II在肝细胞癌诊断及预后判断中的作用[J].临床肝胆病杂志, 2017, 33 (1) :171-174.

[20]KOKUDO N, HASEGAWA K, AKAHANE M, et al.Evidence-based clinical practice guidelines for hepatocellular carcinoma:the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) [J].Hepatol Res, 2015, 45 (2) :123-127.

Relative Articles

[1]	Rongjie LI, Yi PENG, Xiaolong TANG, Decai ZHANG, Shaojun LIU. Establishment of a modified BISAP scoring system and its clinical significance in the early diagnosis and prognostic evaluation of severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2023, 39(10): 2432-2442. doi: 10.3969/j.issn.1001-5256.2023.10.022
[2]	Xichen LIU, Yiying WANG, Manman TONG, Junjie QIN. Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(1): 176-179. doi: 10.3969/j.issn.1001-5256.2021.01.038
[3]	Chen Chuang, Long PeiYun, Chen Jie, Wang Pan, Huang QingYun, Zang YouYa, Deng GuoYu, Lin DongYi, Wang ZongYu. Value of Barcelona Clinic Liver Cancer staging system versus Hong Kong Liver Cancer staging system in predicting the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(3): 530-534. doi: 10.3969/j.issn.1001-5256.2019.03.016
[4]	Tang Ling, Qiu LuDie, Qin Wen, Wu Gang. Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2019.09.019
[5]	Luo Hao, Huang Jun. Clinical value of albumin-bilirubin grade in evaluating the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1608-1612. doi: 10.3969/j.issn.1001-5256.2019.07.040
[6]	Wen XiaJie, Yao MingJie, Zhang Ling, Lu FengMin. Value of common laboratory parameters in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1395-1398. doi: 10.3969/j.issn.1001-5256.2018.07.006
[7]	Luo XinChen, Zhou YouQian. Increasing early diagnosis of primary liver cancer by improving the compliance with regular screening in the high-risk population[J]. Journal of Clinical Hepatology, 2018, 34(8): 1788-1792. doi: 10.3969/j.issn.1001-5256.2018.08.044
[8]	Zhao YunSheng, Zhang LiNa, Huo LiJing, Pei Liu, Li QiuPing, Li HongChen, Jin Liang. Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1707-1711. doi: 10.3969/j.issn.1001-5256.2018.08.023
[9]	Chen MinHua, Wu Wei. Value of contrast-enhanced ultrasound in early diagnosis of liver cancer and radiofrequency ablation treatment[J]. Journal of Clinical Hepatology, 2017, 33(7): 1211-1213. doi: 10.3969/j.issn.1001-5256.2017.07.002
[10]	Wang XianBo, Gao FangYuan, Liu Yao. Neutrophil- lymphocyte ratio: a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 649-652. doi: 10.3969/j.issn.1001-5256.2016.04.007
[11]	Wang Ting, Liu Mei, Dong Lei, Duan ZhongPing. Application of tumor-associated antigens and their autoantibodies in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(7): 1418-1421. doi: 10.3969/j.issn.1001-5256.2016.07.047
[12]	Li Peng, Zhai Yun, Zhang ShiBin, Li Lei, Ding HuiGuo. Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 721-724. doi: 10.3969/j.issn.1001-5256.2015.05.021
[13]	Chen YangQin, Li Peng, Li Lei, Li Bing, Ding HuiGuo. Early diagnosis of nonalcoholic fatty liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1357-1360. doi: 10.3969/j.issn.1001-5256.2014.12.031
[14]	Lu LunGen, Li ZhengHong. Diagnosis and assessment of liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 577-579. doi: 10.3969/j.issn.1001-5256.2014.07.001
[15]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
[16]	Gao HaiFeng. Value of combined detection of serum AFP and GP73 in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(7): 660-662. doi: 10.3969/j.issn.1001-5256.2014.07.022
[17]	Zhu MingYu, Chen Jie, Zhang XinXin. Research advances in serum biomarkers for early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1091-1093. doi: 10.3969/j.issn.1001-5256.2014.10.029
[18]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006
[19]	Li HaiPing, Gao Bo, Yu ZongTao, Liu JiuBo, Zhang JiCai. Significance of detection of multigene methylation in liver cancer tissue for early diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(8): 624-626. doi: 10.3969/j.issn.1001-5256.2013.08.018

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2546) PDF downloads(425)

Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2017.07.019

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2017.07.019

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content